share_log

安科生物(300009.SZ):公司2023年生长激素销售收入接近合并收入的70%

Anke Biotech (300009.SZ): The company's 2023 growth hormone sales revenue is close to 70% of consolidated revenue

Gelonghui Finance ·  May 8 05:06

Gelonghui, May 8, 丨 Anke Biotech (300009.SZ) said on the investor interactive platform that the company's 2023 growth hormone sales revenue was close to 70% of consolidated revenue, and the parent company achieved net profit of 763 million, mainly contributing to growth hormone.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment